Regenxbio Inc (RGNX) showcases robust financial positioning and strategic progress in gene therapy, despite challenges in ...

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the ...

Reports cash, cash equivalents and marketable securities as of December 31 were $383.5M compared to $562.7M as of December 31, 2023. Lyell ...

As of December 31 the Company had $66M in cash and cash equivalents, $83M in marketable securities and $7M in prepaid expenses and other current ...

ContextLogic will host a financial results and strategic update conference call at 5pm EDT on March 12 th. The live conference call may be accessed by registering here. The associated strategic ...

The company said the fiscal 2023 fourth quarter results reflect a goodwill impairment charge of $41.1 million, or $2.13 per ...

As of December 31, 2024, Sutro had cash, cash equivalents and marketable securities of $316.9 million, as compared to $388.3 million as of September 30, 2024. Cash runway is expected into at least Q4 ...